What is Slendesta?
Slendesta®, the newly introduced potato extract Slendesta is a safe, natural satiety ingredient for weight loss containing Proteinase Inhibitor II (PI2), a protein naturally found in white potatoes. Slendesta enhances the release of Cholecystokinin (CCK), the natural signalling peptide within our body. Once released, CCK travels through the blood and acts on various target organs, including the stomach and brain, where it induces feelings of fullness and satisfaction. This feeling of fullness and satisfaction is known as satiety.
Dedicated to improving the health and wellness worldwide, Novum Nutraceuticals, delivers an innovative satiety ingredient to address the global overweight and obesity epidemic and the difficulties that dieters have with losing weight. For years, Many firms have been researching this unique Potato Proteinase Inhibitor II (PI2), originally discovered in the 1960s. CCK was first discovered in 1928 and has been heavily researched in humans for the past twenty-six years. The Novum patent pending technology offers the CCK stimulating benefits of PI2 with its Slendesta Potato Extract.
One of the primary reasons dieters quit their diets is that they feel too hungry. Slendesta helps eliminate that reason by providing satiety. If one feels satisfied, there's less hunger, and less chance of temptation. Slendesta helps dieters feel satisfied sooner and longer, and therefore dieters can manage their hunger, reduce their calorie intake with smaller portions, and control between meal snacking. Reducing calorie intake without hunger helps dieters to meet their weight loss goals.
Eleven clinical studies have demonstrated that PI2 is a safe and effective ingredient that promotes satiety and healthy weight loss. When taken as directed, Slendesta has resulted in statistically significant weight loss and reductions in waist and hip measurements.
Clinical Support Of Slendesta
Slendesta™ is a natural, patented ingredient, an extract of potato protein, standardised in proteinase inhibitors or P12. To date. Over 12 clinical studies suggest that Slendesta™ is a safe ingredient which promotes satiety and healthy weight loss.
What is Proteinase Inhibitor 2
P12 encourages the release of cholecystokinine (CCK), a signalling peptide found naturally in the human body, which induces a feeling of fullness or satiety. Once released, CCK travels via the bloodstream to various organs where it produces a feeling of fullness and satisfaction and thus reduces the urge to eat more. Giving CCK or similar molecules to rats was shown to result in weight loss. Furthermore, rats without CCK receptors became obese and developed related symptoms such as hyperglycaemia or insulin-resistance.
The benefits of P12, the active principle in Slendesta™, have been clinically proven. Taking Slendesta™ leads to statistically significant weight loss as well as reductions in waist and hip measurements.
In diabetic subjects, P12 stimulated the release of CCK and increased the time it took the stomach to empty.
In healthy subjects, P12 reduced energy consumption.
A randomized, placebo-controlled clinical crossover study, involving 45 participants, showed that when Slendesta™ was taken 1 hour before a meal, the feeling of fullness was significantly greater and the urge to eat was reduced. This study also showed that levels of CCK increased, and remained elevated for longer after eating, than was the case in the control group.
Taking P12 was also effective - in a dose-dependent manner - at reducing the glucose peak which normally occurs after a meal. This blood glucose peak causes a rise in insulin which, when occurring on a regular basis, can play a key role in weight gain; taking P12 thus also lowered post-prandial levels of insulin in the blood, an effect that is scientifically recognized to be an important element in weight control.
In a larger randomized, placebo-controlled study of 240 subjects, taking Slendesta™ around 60 minutes before each of two main meals induced significant loss of weight and inches around the waist and hips.
In a 20-week open trial, taking Slendesta™ enabled participants to achieve weight loss of around 5.3 kg by the end of the study, as well as reductions in waist and hip measurements of 16% and 9% respectively, with no side effects.
Taken one hour before each of the day’s two main meals, can thus be considered an effective means of promoting weight loss and controlling weight, and the ideal complement to a low-carb diet and exercise regime.